RECIST

P. Therasse, E.A. Eisenhauer, J. Verweij, RECIST revisited A review of validation studies on tumor assessment, Eur. J. Cancer 42(8) (2006) 1031-1039. 

Ordinal data arises in many situations. In oncology (solid tumours) the RECIST criteria record outcome in one of 4 response categories (National Cancer Institute, WWW. cancer, gov) ... 

RECIST Response Evaluation Criteria in Solid Tumours... 

Reactant ion peak 1347 Rebetron 17 Rebif 17, 467, 1404 RecDNA somatotropin 477 Receptor tyrosine kinase (RTK) 639 RECIST criteria 1259... 

Ratain Ml, Eckhardt SG. Phase II studies of modern drugs directed against new targets if you are fazed, too, then resist RECIST. J Clin Oncol 2004 22 4442-4445. 

Prices ijill soori urily be available ta recistfeJ aser Please Contact rsbli on 020 777G 2533 c reciste". 

Response to therapy is usually measured using the RECIST criteria [59, 60] for morphologic images (MRI, CT, ultrasound). Tumor sizes, however, do not necessarily reflect the number of viable tumor cells. From other types of oncologic therapy (e.g. chemotherapy) it is known that, in the early post-treatment period, the size of the tumor lesions remains constant even though the number of vi-... 

Therasse P, Eisenhauer EA, Verweij J (2006) RECIST revisited a review of validation studies on tumour assessment. Eur J Cancer 42 1031-1039... 

Table9.1. RECIST criteria offer a simplified, conservative, extraction of imaging data for wide application in clinical trials. They presume that linear measures are an adequate substitute for 2D methods and register four response categories...

Mazumdar M, Smith A, Schwartz LH (2004) A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol 57 358-365... 

Fig. 10.1. Changes in tumor burden after therapy. The sum of maximal diameters of target lesions according to RECIST criteria is shown in black solid lines. Number of patients developing new tumor nodules within the liver are shown in bars...

Traditional methods for the evaluation of tumor response to therapy have been size reduction on CT through the application of the WHO or Response Evaluation Criteria in Solid Tumors (RECIST) criteria [73, 74]. However, some pitfalls may occur when those methods based on CT dimensional changes are applied to Y therapy. First, RECIST or WHO criteria do not allow for the use of PET scanning in the follow-up evaluation, thereby ignoring the functional nature of the residual tissue. Further-... 

---